ICON plc - Ordinary Shares (ICLR): Price and Financial Metrics

ICON plc - Ordinary Shares (ICLR)

Today's Latest Price: $199.11 USD

1.67 (0.85%)

Updated Dec 2 4:00pm

Add ICLR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

ICLR Stock Summary

  • Icon Plc's market capitalization of $10,587,168,353 is ahead of 84.14% of US-listed equities.
  • Price to trailing twelve month operating cash flow for ICLR is currently 25.66, higher than 83.06% of US stocks with positive operating cash flow.
  • Revenue growth over the past 12 months for Icon Plc comes in at 78.15%, a number that bests 93.29% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Icon Plc, a group of peers worth examining would be MORN, RBA, HELE, BWA, and MMS.
  • Visit ICLR's SEC page to see the company's official filings. To visit the company's web site, go to www.iconplc.com.

ICLR Stock Price Chart Interactive Chart >

Price chart for ICLR

ICLR Price/Volume Stats

Current price $199.11 52-week high $215.29
Prev. close $197.44 52-week low $104.28
Day low $196.96 Volume 256,436
Day high $200.47 Avg. volume 252,921
50-day MA $194.29 Dividend yield N/A
200-day MA $172.76 Market Cap 10.68B

ICON plc - Ordinary Shares (ICLR) Company Bio

ICON Public Limited Company provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. The company was founded in 1990 and is based in Dublin, Ireland.

ICLR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$199.11$137.22 -30%

Below please find a table outlining a discounted cash flow forecast for ICLR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Icon Plc ranked in the 40th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Icon Plc, consider:

  • Interest coverage, a measure of earnings relative to interest payments, is 33.02; that's higher than 88.53% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 13.59% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • ICLR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 45.37% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ICLR, try STE, REGN, GILD, MEDP, and CRL.

ICLR Latest News Stream

Event/Time News Detail
Loading, please wait...

ICLR Latest Social Stream

Loading social stream, please wait...

View Full ICLR Social Stream

Latest ICLR News From Around the Web

Below are the latest news stories about Icon Plc that investors may wish to consider to help them evaluate ICLR as an investment opportunity.

Healthcare Cro Market MAY SEE A BIG MOVE | Quintiles, Covance, parexel, Charles river laboratories, ICON Plc.

Global Healthcare Cro Market Size Study, By Type (Drug Discovery, Pre-Clinical, Clinical), By Service (Project Management, Data Management, Medical Writing, Technology) And By Regional Forecasts 2025, Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis

OpenPR | September 28, 2020

Forbes names ICON in list of Best Employers in America for Women

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries today announced that it has been recognised in the 2020 Forbes List of America’s Best Employers for Women for the second consecutive year. Forbes collaborated with market research firm Statista, surveying 75,000 Americans, including 45,000 women, working for businesses that employ more than 1,000 workers

Business Wire | August 21, 2020

ICON Plc -- Moody's affirms Baa3 issuer rating of ICON Plc, stable outlook

Moody's Investors Service, ("Moody's") has today affirmed the Baa3 long term issuer rating of ICON Plc ("ICON" or "the company"). ICON is strongly positioned in the Baa3 rating. Additionally, Moody's expects that ICON will continue to have strong Moody's-adjusted EBITDA margins of around 18% to 19%.

Yahoo | July 30, 2020

Icon PLC: A CRO Momentum Stock Worth Backing Long Term

Investment Thesis Icon PLC 5-year share price performance. Source: TradingView. Icon (ICLR) looks like a solid investment opportunity in the contract research organization ("CRO") space, offering strong growth potential whilst being a little undervalued by the market, based on my analysis. Since 2010 Icon has grown its revenues from $0.9bn,...

Edmund Ingham on Seeking Alpha | July 29, 2020

ICON Public Limited Company (ICLR): Were Hedge Funds Right About This Stock?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 28, 2020

Read More 'ICLR' Stories Here

ICLR Price Returns

1-mo 6.86%
3-mo 9.04%
6-mo 22.44%
1-year 24.22%
3-year 70.84%
5-year 170.09%
YTD 15.61%
2019 33.29%
2018 15.21%
2017 49.14%
2016 -3.22%
2015 52.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9344 seconds.